1. Identification and Characterization of Cannabimovone, a Cannabinoid from Cannabis sativa, as a Novel PPARgamma Agonist via a Combined Computational and Functional Study
- Author
-
Elisabetta Panza, Orazio Taglialatela-Scafati, Rosa Maria Vitale, Pietro Amodeo, Luciano De Petrocellis, Fabio Arturo Iannotti, Giovanni Appendino, Fabrizia De Maio, Iannotti, F. A., De Maio, F., Panza, E., Appendino, G., Taglialatela-Scafati, O., De Petrocellis, L., Amodeo, P., and Vitale, R. M.
- Subjects
Agonist ,PPARgamma ,PPARs ,cannabimovone ,medicine.drug_class ,medicine.medical_treatment ,peroxisome proliferator-activated receptor gamma (pparγ) ,Pharmaceutical Science ,Pharmacology ,Molecular dynamics ,Analytical Chemistry ,lcsh:QD241-441 ,03 medical and health sciences ,0302 clinical medicine ,Molecular docking, molecular dynamics, insulin resistance ,cannabimovone (cbm) ,lcsh:Organic chemistry ,insulin resistance ,Drug Discovery ,medicine ,Luciferase ,Physical and Theoretical Chemistry ,phytocannabinoids ,Receptor ,030304 developmental biology ,0303 health sciences ,biology ,Chemistry ,Organic Chemistry ,Lipid metabolism ,Insulin receptor ,Nuclear receptor ,Chemistry (miscellaneous) ,Molecular docking ,biology.protein ,Molecular Medicine ,Cannabinoid ,Phytocannabinoids, cannabimovone (CBM) ,Cannabidiol ,030217 neurology & neurosurgery ,medicine.drug - Abstract
Phytocannabinoids (pCBs) are a large family of meroterpenoids isolated from the plant Cannabis sativa. &Delta, 9-Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the best investigated phytocannabinoids due to their relative abundance and interesting bioactivity profiles. In addition to various targets, THC and CBD are also well-known agonists of peroxisome proliferator-activated receptor gamma (PPAR&gamma, ), a nuclear receptor involved in energy homeostasis and lipid metabolism. In the search of new pCBs potentially acting as PPAR&gamma, agonists, we identified cannabimovone (CBM), a structurally unique abeo-menthane pCB, as a novel PPAR&gamma, modulator via a combined computational and experimental approach. The ability of CBM to act as dual PPAR&gamma, /&alpha, agonist was also evaluated. Computational studies suggested a different binding mode toward the two isoforms, with the compound able to recapitulate the pattern of H-bonds of a canonical agonist only in the case of PPAR&gamma, Luciferase assays confirmed the computational results, showing a selective activation of PPAR&gamma, by CBM in the low micromolar range. CBM promoted the expression of PPAR&gamma, target genes regulating the adipocyte differentiation and prevented palmitate-induced insulin signaling impairment. Altogether, these results candidate CBM as a novel bioactive compound potentially useful for the treatment of insulin resistance-related disorders.
- Published
- 2020
- Full Text
- View/download PDF